Danaher joins bespoke gene therapy consortium (bgtc) for rare diseases

Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies washington , may 12, 2022 /prnewswire/ -- danaher corporation (nyse: dhr) announced that it has joined the bespoke gene therapy consortium (bgtc). launched in october 2021, the bgtc will generate gene therapy resources that the research community can use to streamline gene therapy development for rare disorders, making the process more efficient and less costly.
DHR Ratings Summary
DHR Quant Ranking